Daniel T Lopes

US Patent:

20220249529, Aug 11, 2022

Filed:

Jun 19, 2020

Appl. No.:

17/620545

Inventors:

- San Diego CA, US
Shelonitda ROSE - Branchburg NJ, US
Diana R. DUNSHEE - Alamo CA, US
Daniel E. LOPES DE MENEZES - Berkeley CA, US
Kyle MACBETH - Santa Rosa CA, US
Yumin DAI - Danville CA, US
Jessica JANG - New York NY, US
Mark FRATTINI - Ridgewood NJ, US

Assignee:

CELGENE QUANTICEL RESEARCH, INC. - San Diego CA

International Classification:

A61K 31/706
A61K 31/513
A61K 31/501
A61K 31/407

Abstract:

Provided herein are methods for using 5-azacytidine in combination with additional agents to treat diseases and disorders including AML.

US Patent:

20180179282, Jun 28, 2018

Filed:

Jun 13, 2016

Appl. No.:

15/735055

Inventors:

- Princeton NJ, US
Wendy L. Clemens - Newtown PA, US
Glenn S. Kroog - New York NY, US
Daniel E. Lopes de Menezes - Berkeley CA, US
Chin Pan - Los Altos CA, US
Paul D. Ponath - San Francisco CA, US
Jean Viallet - Malvern PA, US

International Classification:

C07K 16/28
A61P 35/00
C07K 16/24

Abstract:

This disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a combination of therapeutically effective amounts of an antibody or an antigen-binding portion thereof that binds specifically to Programmed Death-1 (PD-1) or to Programmed Death Ligand-1 (PD-L1), and an antibody or an antigen-binding portion thereof that binds specifically to C-X-C Chemokine Receptor 4 (CXCR4) or to C-X-C motif chemokine 12 (CXCL12). The disclosure also provides a kit for treating a subject afflicted with a cancer, the kit comprising one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to PD-1 or to PD-L1, one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to CXCR4 or to CXCL12, and instructions for using the antibodies or portions thereof for treating the subject.